Most adult patients under 60 years with acute myeloid leukaemia (AML) who achieve a complete remission after induction chemotherapy will relapse if they do not receive further therapy. Consolidation treatment with autologous stem cell transplantation (SCT) is one option that has been studied extensively. High-dose cytotoxic therapy followed by autologous SCT or intensive cycles of chemotherapy furnish overall approximately similar probabilities of survival when applied in first remission. Here, we present a concise update regarding the place of autologous SCT in the treatment of AML. Particular issues discussed are the value of autologous SCT in different prognostic subsets of AML and the value of autologous mobilised peripheral blood stem cell transplants, which offer a much faster haematopoietic recovery.

Acute myeloid leukaemia, Autologous stem cell transplantation, Bone marrow, Mobilised peripheral blood stem cells, Prognostic risk groups
dx.doi.org/10.1111/j.1365-2141.2005.05628.x, hdl.handle.net/1765/64849
British Journal of Haematology
Department of Hematology

Breems, D.A, & Löwenberg, B. (2005). Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia. British Journal of Haematology (Vol. 130, pp. 825–833). doi:10.1111/j.1365-2141.2005.05628.x